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Abstract
Background: Despite numerous options for treating back pain and the increasing healthcare resources devoted to
this problem, the prevalence and impact of back pain-related disability has not improved. It is now recognized that
psychosocial factors, as well as physical factors, are important predictors of poor outcomes for back pain. A
promising new approach that matches treatments to the physical and psychosocial obstacles to recovery, the STarT
Back risk stratification approach, improved patients’ physical function while reducing costs of care in the United
Kingdom (UK). This trial evaluates implementation of this strategy in a United States (US) healthcare setting.
Methods: Six large primary care clinics in an integrated healthcare system in Washington State were block-
randomized, three to receive an intensive quality improvement intervention for back pain and three to serve as
controls for secular trends. The intervention included 6 one-hour training sessions for physicians, 5 days of training
for physical therapists, individualized and group coaching of clinicians, and integration of the STarT Back tool into
the electronic health record. This prognostic tool uses 9 questions to categorize patients at low, medium or high
risk of persistent disabling pain with recommendations about evidence-based treatment options appropriate for
each subgroup. Patients at least 18 years of age, receiving primary care for non-specific low back pain, were invited
to provide data 1–3 weeks after their primary care visit and follow-up data 2 months and 6 months (primary
endpoint) later. The primary outcomes are back-related physical function and pain severity. Using an intention to
treat approach, intervention effects on patient outcomes will be estimated by comparing mean changes at the 2
and 6 month follow-up between the pre- and post-implementation periods. The inclusion of control clinics permits
adjustment for secular trends. Differences in change scores by intervention group and time period will be
estimated using linear mixed models with random effects. Secondary outcomes include healthcare utilization and
adherence to clinical guidelines.
Discussion: This trial will provide the first randomized trial evidence of the clinical effectiveness of implementing
risk stratification with matched treatment options for low back pain in a United States health care delivery system.
Trial registration: NCT02286141. Registered November 5, 2014.
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Background
Finding effective and affordable treatments for chronic
pain is a major challenge for clinicians, researchers,
payers, and patients in industrialized countries [1]. Back
pain is the most prevalent and costly type of pain. More
than 50 % of US adults are bothered by back pain each
year and up to 80 % are afflicted by it at some time in
their lives [2]. About $26 billion is spent annually in the
US on personal medical care for back pain [3], and in
2002, the costs of lost worker productivity due to back
pain were almost $20 billion [4]. Despite the growing
number of options available for evaluating and treating
back pain, and the increasing costs of medical care de-
voted to this problem, the health and functional status
of people suffering from back pain in the US has deteri-
orated [5]. The current epidemic of opioid addiction and
deaths among those treated for chronic pain illustrates
the importance and urgency of finding safer and more
effective approaches to relieving chronic pain [6, 7].
There has been an increasing appreciation among ex-
perts of the limitations of the traditional view of back pain
as a largely biomedical problem [8]. More comprehensive
biopsychosocial models acknowledge that chronic pain
usually has an underlying biological basis, but recognize
that psychosocial factors—such as pain beliefs/cognitions,
coping behaviors and the social environment—also signifi-
cantly influence the experience of pain and its effects on
physical, psychological, and social functioning [9, 10]. Re-
search has consistently found strong relationships between
maladaptive beliefs/cognitions and negative pain-related
outcomes [9, 11]. This research provides a clear rationale
for incorporating cognitive behavioral principles into the
management of the distressed and disabled (high risk) low
back pain patients for the purposes of secondary preven-
tion of pain-related disability.
The “Subgroups for Targeted Treatment” (STarT) risk
stratification approach
A promising approach to targeting treatments to sub-
groups of patients, the STarT Back approach [12], has
been found effective in improving patient physical
functioning and satisfaction with care while reducing
costs of healthcare in both physical therapy settings [13]
and family physician practices in the UK [14, 15]
(www.keele.ac.uk/sbst/). The STarT Back approach first
uses a 9-item “STarT Back tool” patient questionnaire to
categorize patients by their risk of persistent disabling
back pain and then identifies the treatments deemed most
appropriate for patients in each subgroup [12, 16, 17]. Pa-
tients found to have 4 or more “psychosocial” risk factors
(pain bothersomeness, fear, worry, catastrophizing, de-
pression) are considered high risk and those with relatively
few (0–3) physical or psychosocial risk factors are consid-
ered low risk. The remaining patients, who have signifi-
cant pain and/or activity limitations but few psychosocial
risk factors, are considered moderate risk. This tool has
been validated for use with primary care adults with non-
specific low back pain [12].
In the UK trial, low risk patients were offered analgesic
medications, reassurance, and advice and education on
self-care; medium risk patients were offered physical
therapy (PT) treatment, and high risk patients were of-
fered PT from therapists who had been specially trained
to elicit and address key psychosocial obstacles to recov-
ery using a psychologically informed physical therapy ap-
proach [18, 19]. The success of this risk stratification
approach in the UK has generated high levels of interest,
providing new hope that meaningful improvements in
primary care for back pain are within reach [20–25].
Will the STarT back risk stratification strategy work in the US?
The MATCH (Matching Appropriate Treatments to Con-
sumers Healthcare needs) trial evaluates implementation of
a version of the STarT Back risk stratification approach
adapted for use in an integrated health care delivery system
in the U.S. serving over 600,000 members—Group Health
(GH) in Washington State. We obtained funding from the
National Institutes of Health (NIH) to evaluate the imple-
mentation process and from the Patient-Centered
Outcomes Research Institute (PCORI) to evaluate the
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effectiveness of this approach. This is the first major evalu-
ation of the risk stratification approach based on the STarT
Back tool for back pain in the US.
Prior to the initiation of the MATCH trial, GH had
communicated elements of the STarT Back approach to
all clinicians via a one-time video-webcast continuing
medical education (CME) presentation. This optional
45-min presentation briefly described the STarT Back
tool and how to access it in the electronic health record
(EHR) as well as GH’s new clinical guidelines for low
back pain. This initial version of the STarT Back tool
was similar but less well-developed than the one used in
the intervention. Neither primary care clinicians nor
physical therapists received any training or support to
implement the STarT Back approach. Not surprisingly,
very few clinicians began using the STarT Back tool fol-
lowing this minimal and passive CME approach and it is
not clear if those who did use it were recommending
treatment options appropriate for the patients’ risk level.
Funding for the MATCH study provided GH an
opportunity to conduct a trial to evaluate full implemen-
tation of the STarT Back approach in the form of a
mandatory quality improvement (QI) initiative. This
manuscript describes the development and implementa-
tion of this QI strategy and the protocol for evaluating
its effectiveness. The goal of this initiative was to give
primary care providers (PCPs) and physical therapists
(PTs) the knowledge, tools, and confidence they needed
to provide their patients with a broader understanding
of their back problem, reassurance that their condition
would likely improve, and provide treatment options
most likely to be helpful. We hypothesized that this QI
intervention would improve patient outcomes by pro-
moting the increased use of effective treatment options
that address patients’ needs.
Methods/design
Development and implementation of the QI strategy
Development and implementation of the risk stratifica-
tion approach included assembly of the project team,
elicitation of perspectives of key stakeholders, selection
of the treatment options to be recommended for each
risk subgroup, programming the EHR to support the
intervention, training the primary care (PC) teams and
PTs, and implementation in three PC clinics where both
the PC teams and PTs are co-located.
Assembled the project team
We developed the QI strategy between March 2013 and
April 2014 with the support of key GH primary care and
PT leaders, several of whom actively served on our
project team (ML, DP, PR). To fully benefit from the ex-
pertise of the UK group that had developed, tested and
implemented the STarT Back approach, we included
three key UK members (NF, JH, GS) on our team. We
also invited four local individuals with extensive personal
experience with chronic pain to serve on our project
team. Three are actively involved in helping others with
chronic pain through classes and support groups. These
“Patient Partners” provided valuable perspectives on the
implementation strategy, including identification of ways
clinicians could more effectively communicate with pa-
tients and outcome measures to use in our evaluation.
Elicited perspectives of key stakeholders
To ensure we understood the perspectives of GH patients
and clinicians on key issues related to the design and im-
plementation of the STarT Back approach we convened 3
focus groups with a total of 28 patients and 3 focus groups
with a total of 15 clinicians (10 PCPs and 5 PTs). To
maximize the potential for efficiently implementing our
intervention strategy in other U.S. healthcare settings, we
recruited a diverse group of national advisors representing
patients, large employers, major governmental and
independent healthcare systems, primary care practice
networks, major government payers and insurers, and in-
stitutions that train complementary and alternative med-
ical care (CAM) providers. Most advisers were in
positions to influence policies within their organizations.
Identified treatment options for each risk subgroup
We used the STarT Back tool without modification, but se-
lected treatment options matched to each risk stratum that
were deemed appropriate for a US, and specifically GH,
setting. We used GH’s new guidelines for assessing and
treating patients with back pain (Additional file 1) to iden-
tify the evidence-based treatment options that could be
matched to each patient subgroup. These guidelines
adapted leading back pain guidelines in the US [26] and
UK [27], for use at GH. For example, the US guidelines rec-
ommend a multi-disciplinary intensive rehabilitation pro-
gram as an option for persistent back pain [26], but this
was not readily available at GH. However, GH patients do
have varying degrees of access to the remaining six treat-
ment options recommended by the US guidelines [26].
CBT (available from GH’s behavioral health service), exer-
cise programs (available from GH PTs), spinal manipulation
therapy (chiropractic)/acupuncture/massage (available to
most GH members through a contracted network of exter-
nal providers), and yoga (available in the community, but
not covered by insurance). Given the similar clinical effect-
iveness observed in previous systematic reviews [28, 29], we
encouraged clinicians to try to interest patients in active
treatments (exercise, yoga) before recommending passive
options (chiropractic, massage, acupuncture).
Clinicians in the intervention clinics were trained to
routinely administer the STarT Back tool to determine
each patient’s risk of persistent disabling pain and to
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tailor their treatment recommendations to the patient’s
risk level [12]. Patients could be offered treatment op-
tions appropriate for patients at lower risk levels. The
treatments recommended for each risk level were:
 Low Risk (~40 % of patients): The PCP can manage
most patients in this category through minimal
interventions without referral to an additional
provider [30]. For these patients the provider should
conduct a brief assessment to rule out potentially
serious causes of back pain (i.e., “red flags”), elicit and
listen to patients’ concerns, provide reassurance about
the positive prognosis and self-care recommendations
to relieve pain (i.e., appropriate physical activity, use
of pain medications and avoiding bed rest). PCPs were
trained and encouraged to recommend that their
patients access online DVDs that reinforced
information about acute or chronic back pain and the
importance of self-care.
 Moderate Risk (~40 % of patients): Patients in this
group should be offered additional guideline-
recommended treatment options, particularly those
involving exercise and activating treatments that
could reduce fear of movement (i.e., PT and yoga).
Patients not interested in activating treatments should
be offered the more passive options (acupuncture,
spinal manipulation, or massage therapy) in the hope
these treatments will help decrease their pain and
prepare them for transition to more active
approaches, including the Living Well with Chronic
Conditions self-management classes available at GH.
 High Risk (~20 % of patients): High risk patients are
on average more complex (distressed and disabled)
than patients in the low or medium risk subgroup,
therefore, in addition to the treatment options for
moderate risk patients, the best available treatment
options for patients in this subgroup at GH was
psychologically-informed practice delivered by PTs
specially-trained for this initiative or referral to a
psychologist for CBT. “Psychologically informed
practice offers a systematic approach to the
integration of physical and psychological approaches
to treatment for the management of people with low
back pain…” [19]. Here, ‘psychological’ refers to the
beliefs/expectations, emotional and behavioral
responses associated with low back. Unfortunately,
access CBT from a psychologist was very limited.
PCPs were also encouraged to proactively follow-up
with high risk patients within 2 weeks.
Incorporated STarT back tool, recommended treatments,
and decision aids into the EHR
GH’s Clinical Informatics specialists had previously in-
corporated the STarT Back tool into its EHR (EpicCare),
but this produced only the total number of risk items en-
dorsed by patients without determination of risk level or
recommendation of appropriate treatments. To resemble
the way the STarT Back tool was used in the UK, we en-
hanced the tool so that after a patient’s responses had
been entered, the EHR automatically calculated the pa-
tient’s risk stratum and displayed the recommended treat-
ment options for that stratum on a screen visible to both
clinicians and patients. This provided an opportunity for
clinicians to discuss treatment options with their patients.
Providers had the option of including this information in
the patient’s after visit summary. To promote routine use
of the STarT Back Tool, we let clinics and clinicians de-
cide how to most consistently and efficiently collect and
enter the STarT Back Tool data into the EHR. Although
the process varied, most clinicians had their medical assis-
tants collect the data either on a paper copy and then
enter it into the EHR, or enter it directly into the EHR.
Shortcuts were incorporated into the EHR to help
clinicians efficiently access these tools and the GH
back pain guidelines and link patients with existing
GH educational resources (DVDs about acute and
chronic back pain, and when surgery might be
indicated) including GH’s self-management groups for
persons with chronic conditions (Living Well With
Chronic Conditions).
Developed training modules for primary care teams
We developed a package of 6 one-hour training sessions
to be presented in each of the 3 primary care interven-
tion clinics (Table 1). Each topic was presented on sev-
eral occasions to ensure that all PCPs participated.
Sessions were presented roughly monthly over a 6-
month period (May – October, 2014). Training focused
on the STarT Back tool and matched treatment options
(emphasizing the importance of the biopsychosocial
model), techniques and strategies for talking about
chronic pain with patients, the special training GH PTs
had received in incorporating simple CBT techniques
into their PT practice to use with high risk patients, and
understanding the role of evidence-based CAM therap-
ies. Physical therapists and members of the nursing staff
were invited to attend several of the sessions.
PCPs and staff received coaching on how to locate and
correctly use the STarT Back and other related tools in
the EHR. This coaching was usually done with one or in-
dividuals. Usually team members with the same role
were paired. Each session lasted approximately 30 min
and took place at work stations. Most PCPs participated
in at least one coaching session.
Finally, to reduce knowledge barriers to recommend-
ing evidenced-based treatment options, we compiled a
list of the names and contact information of meritorious
CAM providers and made them available to clinic staff.
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We did this by asking clinicians in each intervention
clinic to identify local acupuncturists, chiropractors, and
massage therapists covered by GH insurance to whom
they had become comfortable referring their patients
with back pain. We also asked clinicians to recommend
local yoga classes (not covered by insurance).
Training for physical therapists
The PTs in the intervention clinics received five days of
training from a UK instructor (GS) who had trained the
PTs in the original STarT Back Trial and IMPaCT Back
study [18]. This training built upon the established pro-
fessional expertise of Physical Therapists by paying spe-
cific and systematic attention to the psychosocial factors
that are associated with a poor treatment outcome in
people low back pain. To maximise PT effectiveness, the
training included the key psychosocial variables that can
contribute to the development and maintenance of pain
related disability, a focus on raising clinician awareness
about why people in pain think, feel and behave the way
they do and to helping them apply pain relevant psycho-
logical theories and practice to their assessment and
management of low back pain patients (Table 2). Follow-
ing the training, the PTs were expected to begin using
the STarT approach in their practices.
A psychologist on the team with expertise in CBT and
chronic pain (BB) helped facilitate the training and inter-
acted regularly with the PTs after the training. Two
months after the formal training he conducted consult-
ation meetings at each of the intervention clinics. These
meetings, which reviewed how to use the tool and how to
talk with patients about pain, provided therapists support
for continuing to use the new approaches they had
learned. In later sessions, PTs discussed experiences with
Table 1 Overview of Training Sessions for Primary Care
Providers (PCPs) in Intervention Clinics
Overview
Session 1 Introduction
Physician leader of the back pain care quality improvement
project introduced the researchers, the rationale and
importance of reorganizing care for back pain and overview
of the project aims and activities. Focused on getting
clinicians to support the project and excited about the
opportunity to improve back pain care in their clinics.
Introduced the STarT Back tool and risk stratification strategy.
Session 2 Using the STarT Back Tool
Focused on getting PCPs and staff comfortable with
administering the STarT Back approach, including use in the
EHR (EPIC), scoring of tool, and understanding matched
treatment recommendations for each risk level. Discussions
of how to find and use the GH Back Pain Guidelines, attach
the STarT Back tool in secure messages to patients, enter
patient responses into the EHR, view results, use tools
within the EHR to enhance visits for back pain such as
patient instructions and ordering patient centered back
pain (acute and chronic) DVDs.
Session 3 Improving Diagnosis and Ruling out Red Flags
Check-in on clinic’s use of the STarT Back tool. Used patient
case examples to provide a “refresher” on how to conduct
differential diagnoses of common back pain problems
(focused on lower back, L2-L4, L5, S1). Reviews included how
to conduct an efficient exam, common errors in
examinations, appropriate use and interpretation of
diagnostic imaging, red flags for serious conditions,
how to communicate to patients during the examination.
Session 4 Talking with Patients about Chronic Pain
Training focused on ways to communicate more effectively
with patients about chronic pain including: 1) preferred
language in discussing pain, 2) ways to better communicate
anatomical links to pain, 3) explaining what chronic pain is
(pain centralization, gate theory, reoccurrence of pain –
having continued pain with no injury), 4) talking about red
flags and when to return to primary care, 5) focusing on
improving function rather than reducing pain, and 6) how to
discuss outcomes from the STarT Back tool and shared
decision making around treatment options.
Session 5 Improving Partnership between PCPs and PTs
This session brought together PCPs and PTs for an interactive
discussion on how to improve team based care for patients.
Topics included: how PT was providing improved care based
on training, shared responsibility and roles of providers, how
to integrate the STarT Back tool across the departments, and
how to collaboratively work together to help patients not
showing improvement.
Session 6 Complementary and Alternative Medicine Treatments for
Chronic Back Pain
Focused on building an understanding of the role that CAM
providers (acupuncturists, chiropractors, massage therapists)
and yoga classes can play for back pain patients. Emphasized
practical information: brief description of each CAM modality,
scientific evidence for their effectiveness, contraindications,
dosing. CAM therapies referrals were linked to STarT Back
tool risk category, emphasized the use of active over passive
therapies, and how to conduct referrals within the healthcare
system.
Table 2 Physical Therapy Training
Planned Topics
Day 1 • Description of STarT Back Trial, IMPACT study and
other related research
• Description of stratified care
• Myths and facts about patients that have chronic pain
• Research on pain models, the complexity of pain
experiences, with special emphasis on moving away
from seeing pain as an indication of tissue damage.
• Research on neurophysiology of pain
Day 2 • Research on neurophysiology of pain (continued)
• Review of key factors that contribute to development
and maintenance of pain related disability
• Communication skills for working with patients with
disabling chronic pain
Day 3 • Assessment of high risk patients
• Managing/treating high risk patients
• Integrating the psychosocial approach into manual
therapy
Day 4 • Explaining pain
• Managing expectations
• Facilitating behavioral change/goal setting
Day 5 • Managing disability
• Vocational rehabilitation
• Clinical decision making and treatment planning
• Monitoring and modifying treatment plans
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specific patients to highlight effective strategies for incorp-
orating what they had learned into their practice. BB facili-
tated at least 4 of these sessions per clinic over a 6-month
period. In addition, one-on-one training was targeted at
PTs with specific needs.
Implemented risk-stratification strategy
Prior to implementation, we met with the primary
care and PT teams at the intervention clinics to ori-
ent them to the study and explain how it fit into
GH’s broader clinical improvement initiative for back
pain. Over the next six months (May 2014 – October
2014), we worked with primary care and PT leaders
to implement training.
Protocol for evaluating the effects of implementing the
STarT back strategy
We evaluated the intervention’s effect on patients and
healthcare utilization, including adherence to best prac-
tice guidelines. We also collected data that allowed us to
evaluate the implementation process itself (reported
separately).
Effect on patient outcomes
The primary focus of our evaluation is on patient out-
comes. The basic study approach was to determine if pa-
tient outcomes measured 2 and 6 months after a visit
for back pain were better after implementation of the
quality improvement strategy than before (Fig. 1). We
first randomly assigned one clinic from each of 3 pairs
of large primary care clinics (matched on geographic re-
gion and sociodemographic characteristics of the patient
populations) to receive the intervention. Implementation
at the clinic level also minimizes differences in the
patient populations in the intervention and control
groups. Implementation at the clinic level also mini-
mizes risks of contamination and training costs and re-
flects the most practical approach for real-world
healthcare systems. The inclusion of control clinics al-
lows us to adjust the analyses for concurrent changes
that may be occurring in GH primary care clinics during
the intervention period. Randomization within matched
pairs of clinics avoids biased allocation.
To estimate the effects of the intervention on patient
outcomes, we compared the extent of improvement 2
and 6 months after a back pain visit during the pre-
implementation period with that for the post-
implementation period. For both periods, we identified
patients within one week of a primary care visit for non-
specific back pain, mailed letters inviting participation,
collected baseline data within 3 weeks of the index visit,
and then assessed outcomes 2 and 6 months later. This
allowed estimation of the degree of improvement in dys-
function and pain intensity outcomes occurring prior to
implementation of the risk stratification strategy in both
the intervention and control clinics. Beginning about
10 weeks after the end of the 6-month implementation
phase in the intervention clinics, we repeated the
pre-implementation process of estimating the degree
of improvement in the intervention and control
clinics. Patients providing data during the pre-
intervention period were excluded from the post-
intervention period. We will estimate the effect of
the intervention in the intervention clinics by com-
paring the pre-post differences in the intervention
clinics with those in the control clinics and thus ac-
counting for any secular trends over the course of
the study.
Randomized
3 matched
pairs of clinics
STarT BACK QUALIY 
IMPROVEMENT 
INTERVENTION (n=3)
Measured patient 
improvement 2 & 6 
months after visit 
(n=440)
Intervention 
Implemented
Measured patient 
improvement 2 & 6 
months after visit 
(n=440)
Pre-post difference in intervention clinics
1
USUAL CARE 
CONTROL (n=3)
Measured patient 
improvement 2 & 6 
months after visit 
(n=440)
Measured patient 
improvement 2 & 6 
months after visit 
(n=440)
Pre-post difference in control clinics
2
Pre-
Implementation 
Period
Post-
Implementation 
Period
Effect of Intervention = Pre-post difference in intervention clinics [ ] minus pre-
post difference in control clinics [  ] (controls for effects of time) 
1
2
Fig. 1 Study Design
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Patient recruitment
We used the EHR to identify all adult patients (18+ years
old) who received “primary” (i.e., first-listed) diagnoses con-
sistent with non-specific back pain (e.g., lumbago, back pain
not otherwise specified). To maintain broad applicability of
the study population we only excluded patients with spe-
cific causes of their pain (such as pregnancy, disc hernia-
tion, vertebral fracture, or spinal stenosis) or whose pain
resulted from a job injury since these patients are directed
to the GH Occupational Medicine clinic. Otherwise, all pa-
tients visiting GH PCPs for non-specific back pain were eli-
gible for the study.
Within one week of their visits for back pain, patients
were mailed letters informing them that GH was surveying
patients in an effort to improve its care for back pain. Pa-
tients receiving care from the intervention clinics were not
aware that a QI activity was occurring. The letter stated that
a research specialist would call them within a few days to in-
vite their participation. A phone number was provided for
those not wishing to be contacted. Research specialists
called patients between 1 and 3 weeks after their back pain
visits to explain the study, answer questions, confirm eligibil-
ity and obtain verbal informed consent for participation in a
baseline and two follow-up interviews. To maximize partici-
pation and follow-up rates, we offered patients $20 for com-
pleting each questionnaire. This recruitment process
continued until we reached our required sample size for the
pre-implementation and the post-implementation periods.
Data were collected by trained interviewers using a
computer-assisted telephone interview (CATI) version of
the questionnaires to minimize errors and missing data.
We tracked the disposition of the consecutive patients
seen in the primary care clinics, noting how many were
successfully contacted by phone, agreed to participate,
and completed each questionnaire.
Patient outcome measures (Table 3)
Primary outcomes
During both the pre- and post-intervention periods we
measured outcomes between about 2 weeks (range: 1 to
3 weeks) after the index clinician visit (baseline) and
again two and six months later. We included two
primary patient outcome measures. Back-related phys-
ical function in the previous week was measured with
the modified Roland-Morris Disability Questionnaire
(RMDQ) [31]. This instrument asks 23 yes/no questions
selected for their relevance for patients with back prob-
lems. The RMDQ has been found reliable, valid, and
sensitive to clinical changes [32, 33]. We also asked pa-
tients to rate their back pain severity during the previous
week on a 0-to-10 scale where 0 represents “no pain”
and 10 “pain as bad as it could be.” Such numerical rat-
ing scales have been found to be valid and reliable mea-
sures of pain [34].
Secondary outcomes
We measured the following secondary outcomes:
o Depression was measured with the Patient Health
Questionnaire-8 (PHQ-8) [35], which is identical to
the PHQ-9, but does not assess suicidal ideation. It
has been found reliable, valid, and responsive to
change [36, 37].
o Anxiety was measured with the Generalized Anxiety
Disorder scale (GAD-7), which has good reliability
and criterion, construct, factorial, and procedural
validity in primary care populations [38, 39].
o Fear of movement was measured by an abbreviated
version of the Tampa Scale for Kinesiophobia, a
validated 17-item questionnaire that quantifies
excessive fear of (re)injury due to movement in pain
Table 3 Key Content of Baseline and Follow-up Assessments
Measures Baseline 2-month 6-month
Baseline Characteristics
Patient characteristics: education,
income, employment). (Age,
gender, race, and ethnicity
extracted from EHR)
x
Back pain problem
(duration, pain elsewhere)
x
Risk of Poor Outcome
(STarT Back tool)
x x x
Primary Outcomes
Back pain-related physical
function (RMDQ)
x x x
Back pain severity (0–10 scale) x x x
Secondary Outcomes
Depression (PHQ-8) x x x
Anxiety (GAD-7) x x x
Fear of movement
(TKS-10 item version)
x x x
Global improvement (PGIC) x x
Self-efficacy (PSEQ) x x x
Patient satisfaction with caring,
information, treatment effectiveness
x x x
Work loss in past 7 days due to LBP
(hours); Effect on work productivity
(0 to 10 scale) (2 items from WPAI)
x x x
Treatment-Related Information
Helpfulness of treatments
recommended by PCPs
x x
Medications used in past week;
change in medication use over time
x x x
Out-of-pocket expenses x x
Abbreviations: EHR, Electronic Medical Record; RMDQ, Roland Morris Disability
Questionnaire; PHQ, Patient Health Questionnaire; GAD, Generalized Anxiety
Disorder scale; TKS, Tampa Kinesiophobia Scale); PCIG, Patient Global
Impression of Change scale; PSEQ, Patient Self Efficacy Questionnaire; WPAI,
Work Productivity and Activity Impairment
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patients [40]. The 10-item version was developed for
another trial [41] had a measure of internal
consistency of 0.66 [Michael von Korff, personal
communication, May 1, 2016]. The total score of the
10 items was adjusted to yield a total score
comparable to the 17-item version by multiplying the
average item score for the items answered by 17.
o Global improvement with treatment. We used the
Patient Global Impression of Change (PGIC) scale
[42], a single question asking participants to rate
improvement with treatment on a seven-point scale
ranging from “very much improved” to “very much
worse,” with “no change” as the mid-point.
o Self-efficacy was measured using the 10-item Pain Self
Efficacy Questionnaire (PSEQ). It shows good
internal consistency and construct validity [43].
o Satisfaction with care was measured using a 10-item
instrument that has been validated and able to
distinguish among three dimensions of satisfaction
(caring, information and treatment effectiveness) [44].
o The Work Productivity and Activity Impairment
(WPAI) is a self-administered instrument used to
evaluate the impact of back pain on productivity. It
assesses time missed from work (absenteeism),
impairment while working/reduced on-the-job
effectiveness (presenteeism), and overall work
productivity loss (absenteeism v. presenteeism). It has
been found reliable, valid, and responsive to change
for several medical conditions [45].
o Use of back-related medications and exercise in the
past week and treatments (e.g., yoga) paid for out of
pocket (which are not captured in the GH database).
Statistical analysis plan and sample size calculations
Statistical analysis plan
The primary purpose of this trial is to estimate the ef-
fectiveness of the risk stratification strategy for reducing
patient dysfunction and pain severity related to back
pain. We also are conducting pre-specified subgroup
analyses to assess risk-strata-specific differences in phys-
ical function and pain severity in the intervention and
control group since we hypothesize there will be more
benefit in the medium and high risk strata.
To evaluate the overall effectiveness of the proposed
risk stratification intervention we estimate the difference
in change scores between the control and intervention
groups, while accounting for possible effects due solely
to the difference in calendar time between the pre- and
post-implementation periods (Table 4). Potential effects
such as seasonal trends and health care system policy
changes will be accounted for in our analyses by using
information from concurrent control clinics during the
same period of time. The primary analysis time point for
the study is 6-months following baseline, though we will
also evaluate 2-month changes.
Differences in change scores by intervention group
and time period will be estimated using linear mixed
models (LMM) [46] with random effects to control for
correlation within provider, clinic, or both. Including
random effects in the model will yield valid statistical in-
ference while increasing the overall statistical efficiency
of the pre- and post-treatment design. The general mean
model framework will be the following:
E Yð Þ ¼ β0 þ β1CompStrat þ β2Post
þ β3CompStratPost þ β
!
4Z
!
;
where Y is the change score for the specified follow-up
time (t = 2 or 6 months), CompStrat indicates
randomization to either a risk stratification or a control
clinic, Post is 1 if the patient entered the study during
the post-intervention period and 0 if they entered in the
pre-intervention period, and Z
!
is a vector of potential
baseline confounders to be controlled for in the analysis.
Baseline variables that have previously been shown to be
related to dysfunction and pain intensity outcomes in-
clude age, gender, RMDQ and pain severity scores, dur-
ation of pain, medication use, work-related exertion,
overall health status, and psychological issues related to
health [47–49]. To control for any additional confound-
ing, we will also adjust for baseline variables that are as-
sociated with the changes in RMDQ and pain intensity
Table 4 Estimates of 6-month change in primary outcomes estimated from proposed model, by period of time and randomization group
Period of time Usual Care (UC) Clinics Risk Stratification (RS) Clinics Column Difference
Pre-implementation*
of risk stratification (RS)
β0: Change score in UC clinics
pre-implementation of RS
β0+ β1: Change score in RS clinics
pre-implementation of RS
β1: Difference in change scores due to
RS in the pre-implementation period.
Post-implementation of
risk stratification (RS)
β0+ β2: Change score in UC clinics
post-implementation of RS
β0 + β1 + β2 + β3: Change score in RS
clinics post-implementation of RS
β1 + β3: Difference in change scores due
to RS in the post-implementation period.
Row Difference β2: Difference in change scores due
solely to time (implementation period).
β2 + β3: Difference in change scores
due to time and RS.
β3: Difference in change scores due solely
to the RS implementation.
Abbreviations: UC, usual care, RS, risk stratification
*Clinics randomized to implement the risk stratification intervention will do so only in the latter of the two time periods
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and are imbalanced between the intervention groups, or
between pre and post time periods.
This model framework allows for the calculation of the
confounder-adjusted difference between change scores in
the risk stratification and control groups (β3) taking into ac-
count changes due solely to time period (β2). Table 4 sum-
marizes quantities of interest and their respective parameter
estimates from the model. The model presented here is a
simplified version of what will actually be used for the final
analysis. In the complete model we will include both follow-
up times in the same model to more efficiently estimate the
effects at each time point (efficiency gained from estimating
confounder model parameters just once). We will use the
same model framework to calculate the risk-stratum specific
estimates and secondary outcomes. For binary secondary
outcomes we use generalized linear mixed models (GLMM)
[50] with logistic or log link functions to estimate odds ra-
tios or relative risks instead of mean change scores.
We gave respondents $20 per completed follow-up
questionnaire to minimize missing data. Further, we are
using a model framework of LMM and GLMM models
that assume data are missing at random given baseline
confounders. We will also conduct sensitivity analyses
using imputation to assess the missing data assumptions.
Sample size calculation
We based our power on detecting clinically meaningful
differences of 2.5 points on the RMDQ score and 1.5
points on the pain severity score reported in the litera-
ture [31]. We assumed that within the medium- and
high- risk groups clinically meaningful differences will
be observed in the change scores between intervention
and control groups, but within the low- risk group we
assumed that there will not be significant differences.
We assumed that the baseline distribution of the risk
stratification groups will be 40 % low- risk, 40 %
medium- risk and 20 % high- risk [51]. Therefore the
overall effect difference between the intervention and
control groups would be 1.5 points (0*0.4 + 2.5*0.4 +
2.5*0.2) for RMDQ and 0.9 points for pain intensity.
These differences in mean change scores correspond to
standardized effect sizes of 0.30 and 0.36 for RMDQ and
pain severity, respectively. We assume a standard devi-
ation of 5 points for the RMDQ score and 2.5 for pain
intensity based on previous studies [52–54]. For simpli-
city we have determined the sample size assuming no
correlation of outcomes within provider or clinic, yield-
ing conservative estimates of sample size (larger sample
size than may be required). Most cluster randomized de-
signs require an increase in sample size relative to inde-
pendent randomization, but because we have included a
cluster with cross-over design (pre versus post) it is a
more efficient design than independent randomization.
The same model specified in the previous statistical
analysis section was used for the sample size and power
calculations. For simplification we have set β0, β1, and β2
all to 0 since their values do not affect the power of β3,
the estimate of interest. When estimating β3 we use the
full model including estimates for β0, β1, and β2 to arrive
at the correct power estimates. Power calculations as-
sumed two-sided tests at the 0.05 α-level and were per-
formed using R version 2.14.0 for Windows XP
Professional.
A total sample size of 1,410 participants provides 80 %
power to detect a between-group, overall, standardized ef-
fect size of 0.30 on the RMDQ. This sample size provides
approximately 92 % power to detect a standardized effect of
0.36 for pain intensity. We assumed that 20 % of partici-
pants would drop out of the study and thus inflated the esti-
mated sample size of 1,410 to 1,763. The inflated sample
size of 1,763 was divided into four equal groups correspond-
ing to intervention and control clinics in both the pre- and
post-intervention. The result was rounded down to a final
sample size of 1,760 participants (4 groups of 440). Within
risk strata groups we estimate >90 % power to detect an
effect size of 0.50 (2.5 points on the RMDQ score) for the
medium- and high- risk groups combined, and ~80 %
power to detect an effect size of 0.68 (3.4 points on
RMDQ) for just the high- risk group. Similarly, for pain
intensity, the study will have >95 % power to detect an ef-
fect size of 0.60 (1.5 points) for the pooled medium- and
high- risk groups, and ~80 % power to detect an effect size
of 0.68 (1.7 points) in the high- risk group. Therefore we
have adequate power for all comparisons of interest. Add-
itionally, though there may not be sufficient power to de-
tect the noted effect sizes, we will also estimate the effect
of the intervention separately in each of the risk strata.
Effect on utilization and quality of care
The same analytic approach used to evaluate patient
outcomes will be used to evaluate the effect of the inter-
vention on utilization of health care services for back
pain. We will use EHR data to determine the percentage
of patients with non-specific back pain in the interven-
tion clinics who had a STarT Back risk score recorded
and the effect of the intervention on the frequencies
with which specific tests and treatments for back pain
were used. We will also determine if the observed
changes in utilization following the intervention indi-
cated improvements in the quality of care. Specifically,
we will examine if the use of guideline-recommended
treatments for medium and high risk patients (i.e., PT
which includes exercise, CAM, CBT) increased and the
use of treatments that are generally not recommended
for non-specific back pain (e.g., advanced imaging, opi-
oids, neurosurgery visits, and epidural steroid injections)
decreased. These analyses will be done for all patients
and within each risk stratum. We will conduct two sets
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of analyses, one including only patients who agreed to
participate in the follow-up study and the other includ-
ing all patients who were eligible to participate. The pri-
mary analysis will include all patients since this will best
capture the overall effect of the intervention. Compari-
son of the two analytic populations will allow us to de-
termine how representative patients agreeing to
participate were of all patients in terms of utilization.
Discussion
This trial will provide the first randomized trial evidence
of the effectiveness of implementing risk stratification in
as US setting based on the STarT Back approach. Major
strengths of our trial are the use of an unbiased method of
allocation (randomization) of PCP clinics to the interven-
tion or control groups, inclusion of a pre-intervention
period to adjust the analyses for baseline differences be-
tween the intervention and control clinics, and the use of
a multi-faceted and comprehensive approach conducted
in the context of a system-supported quality improvement
strategy. The main limitations are the restriction to clinics
in one health care system, the inclusion of a small number
of clinics, and the collection of “baseline” data about
2 weeks following the back pain visit. The findings of this
trial will be disseminated through publications in targeted
journals, presentation to the diverse group of national ad-
visors representing key stakeholders assembled for this
study, presentation at conferences, and reports by the
study sponsors. Given the effectiveness of the STarT Back
approach in the UK’s National Health Service setting and
the hope of health care systems in many other settings
and countries that implementing a similar approach will
lead to improvements in care for back pain, the results of
this trial will be of great interest.
Additional file
Additional file 1: Non-specific Back Pain Assessment, Management, and
Follow-up Guideline. (DOCX 176 kb)
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